Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma

Bendamustine for indolent NHL was assessed in three phase III trials, it was assessed in one phase III trial for patients with CLL and in one phase III clinical trial for multiple myeloma. In addition, six phase II trials of bendamustine in indolent NHL have been published and one phase II trial in CLL. No full publication of phase II trials in multiple myeloma was identified. Bendamustine can be seen as additional therapeutic option for some patients with indolent NHL. Although data indicating improvements in progression-free survival, it is difficult to conclusively judge the potential clinical benefit associated with bendamustine therapy in this indication. Second, based on the available evidence bendamustine can be seen as salvage therapy for patients with CLL. Regarding its use in multiple myeloma, bendamustine is recommended as salvage therapy due to limited evidence for bendamustine in this indication.